252 related articles for article (PubMed ID: 11030464)
1. Combination chemotherapy for hepatitis B virus: the path forward?
Shaw T; Locarnini S
Drugs; 2000 Sep; 60(3):517-31. PubMed ID: 11030464
[TBL] [Abstract][Full Text] [Related]
2. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.
Delaney WE; Locarnini S; Shaw T
Antivir Chem Chemother; 2001 Jan; 12(1):1-35. PubMed ID: 11437320
[TBL] [Abstract][Full Text] [Related]
3. The impact of human immunodeficiency virus on viral hepatitis.
Mallet V; Vallet-Pichard A; Pol S
Liver Int; 2011 Jan; 31 Suppl 1():135-9. PubMed ID: 21205151
[TBL] [Abstract][Full Text] [Related]
4. Latest developments in the treatment of hepatitis B.
Dandri M; Petersen J
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
[TBL] [Abstract][Full Text] [Related]
5. Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV.
Wursthorn K; Buggisch P; Lutgehetmann M; Zollner B; Petersen J
Antivir Ther; 2006; 11(5):647-52. PubMed ID: 16964835
[TBL] [Abstract][Full Text] [Related]
6. Toward elimination and eradication of hepatitis B.
Chen DS
J Gastroenterol Hepatol; 2010 Jan; 25(1):19-25. PubMed ID: 20136972
[TBL] [Abstract][Full Text] [Related]
7. Failure of combination therapy with lamivudine and famciclovir following lamivudine monotherapy for hepatitis B virus infection in patients coinfected with human immunodeficiency virus-1.
Matthews GV; Pillay D; Cane P; Ratcliffe D; Gazzard B; Nelson M
Clin Infect Dis; 2001 Dec; 33(12):2049-54. PubMed ID: 11698987
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
9. Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections.
Sagoe KW; Duedu KO; Ziga F; Agyei AA; Adiku TK; Lartey M; Mingle JA; Arens M
Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):38. PubMed ID: 27251610
[TBL] [Abstract][Full Text] [Related]
10. Current treatment of HIV/hepatitis B virus coinfection.
Iser DM; Sasadeusz JJ
J Gastroenterol Hepatol; 2008 May; 23(5):699-706. PubMed ID: 18410604
[TBL] [Abstract][Full Text] [Related]
11. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects.
Puoti M; Airoldi M; Bruno R; Zanini B; Spinetti A; Pezzoli C; Patroni A; Castelli F; Sacchi P; Filice G; Carosi G
AIDS Rev; 2002; 4(1):27-35. PubMed ID: 11998781
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
Jain MK; Comanor L; White C; Kipnis P; Elkin C; Leung K; Ocampo A; Attar N; Keiser P; Lee WM
J Viral Hepat; 2007 Mar; 14(3):176-82. PubMed ID: 17305883
[TBL] [Abstract][Full Text] [Related]
14. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
Bihl F; Martinetti G; Wandeler G; Weber R; Ledergeber B; Calmy A; Battegay M; Cavassini M; Vernazza P; Caminada AP; Rickenbach M; Bernasconi E;
BMC Gastroenterol; 2015 Jul; 15():79. PubMed ID: 26152237
[TBL] [Abstract][Full Text] [Related]
15. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral therapy and HIV/hepatitis B virus coinfection.
Benhamou Y
Clin Infect Dis; 2004 Mar; 38 Suppl 2():S98-103. PubMed ID: 14986281
[TBL] [Abstract][Full Text] [Related]
17. Assessment of treatment efficacy in HBV infection and disease.
Zoulim F
J Hepatol; 2006; 44(1 Suppl):S95-9. PubMed ID: 16352365
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls.
Levy V; Grant RM
Clin Infect Dis; 2006 Oct; 43(7):904-10. PubMed ID: 16941375
[TBL] [Abstract][Full Text] [Related]
19. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
20. Treatment of HIV/HBV coinfection: clinical and virologic issues.
Thio CL; Locarnini S
AIDS Rev; 2007; 9(1):40-53. PubMed ID: 17474312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
